API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

How to synthesize Brexanolone?

Developed by Sage Therapeutics, brexanolone was approved by the USFDA as a first-in-class treatment for PPD in adult women.

Jan 8,2024  API

2-Methyl-3-(3,4-methylenedioxyphenyl)propanal induces Ca2+ decrease and serotonin secretion via a PKG-mediated pathway

2-Methyl-3-(3,4-methylenedioxyphenyl)propanal can induce a dose-dependent decrease in Ca2+ levels in QGP-1 cells, potentially important for fragrance development and olfactory research.

Jan 8,2024  API

Fenbendazole: An Antitumor Agent with Effects on Bone Marrow and Immune System

Fenbendazole shows potential antitumor effects in studies and further research finds its associated risks and complex effects on the bone marrow and immune system.

Jan 8,2024  API

Potassium Sorbate: Versatile and Effective Food Preservative with Alkylating Potential

Potassium sorbate is a commonly used food preservative with low toxicity and high solubility and exhibits alkylating potential, but further research is needed on its implications for human health.

Jan 5,2024  API

A relaxed-state (R-state) stabilizer of hemoglobin: Voxelotor

Voxelotor, also known as GBT440, is a relaxed-state (R-state) stabilizer of hemoglobin developed by Global Blood Therapeutics and approved by the USFDA for treating sickle cell disease.

Jan 5,2024  API

The Synthesis method of Esaxerenone

Esaxerenone, a novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) discovered by Exelixis and developed by Daiichi Sankyo, was approved in Japan to treat hypertension.

Jan 5,2024  API

A brief introduction to triclabendazole

Triclabendazole, also known as CGA 89317 or CGP 23030, is an orally bioavailable anthelmintic against infections caused by Fasciola species.

Jan 5,2024  API

How to synthesize Relebactam?

Relebactam, formerly MK-7655, is a DBO that promises to contribute to the renaissance in antimicrobial chemotherapy.

Jan 5,2024  API

The Synthesis method and Pharmacokinetics of Pretomanid (PA 824)

Pretomanid (also known as PA 824) is a nitroimidazooxazine antimycobacterial drug with a complex mechanism of action.

Jan 5,2024  API

A semisynthetic pleuromutilin antibiotic: Lefamulin

Lefamulin, a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults.

Jan 5,2024  API
Prev12345678910...Next>  Go to Page